The credit evaluation system for pharmaceutical companies introduced in 2020 will be revised. This is according to several sources familiar with the matter, as reported by the business magazine Yicai. They claim that a revised system will be used to monitor unfair prices and marketing practices by companies even more closely, thereby preventing excessive prices for drugs.
The pharmaceutical market in China has been plagued by commercial bribery and price fixing in tenders for years. This leads to inflated prices for drugs and medical products. Additionally, the government has largely restricted access to foreign medicines within the public healthcare system.